Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).

Journal for immunotherapy of cancer - 22 Jun 2018

Danaher Patrick, Warren Sarah, Lu Rongze, Samayoa Josue, Sullivan Amy, Pekker Irena, Wallden Brett, Marincola Francesco M, Cesano Alessandra

Abstract excerpt

The Tumor Inflammation Signature (TIS) is an investigational use only (IUO) 18-gene signature that measures a pre-existing but suppressed adaptive immune response within tumors. The TIS has been shown to enrich for patients who respond to the anti-PD1 agent pembrolizumab. To explore this immune phenotype within and across tumor types, we applied the TIS algorithm to over 9000 tumor gene expression profiles...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptive Immunity
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Computational Biology

Share to Genome, Human

Share to Inflammation

Share to Transcriptome

Share to Tumor Escape

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 29929551
DOI: 10.1186/s40425-018-0367-1
PMCID: PMC6013904

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).PMID 29929551Read ↗

The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.Semantic proximity Read ↗

Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types.Semantic proximity Read ↗

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapySemantic proximity Read ↗

Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathologySemantic proximity Read ↗

Pan-cancer tumor classification by a holistic tumor microenvironment atlasSemantic proximity Read ↗

Development and Performance of a CD8 Gene Signature for Characterizing Inflammation in the Tumor Microenvironment across Multiple Tumor TypesSemantic proximity Read ↗

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.Semantic proximity Read ↗

The Immune Landscape of CancerSemantic proximity Read ↗

A single-cell pan-cancer analysis to show the variability of tumor-infiltrating myeloid cells in immune checkpoint blockadeSemantic proximity Read ↗

The epiphany derived from T-cell–inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responsesSemantic proximity Read ↗

Pan-cancer landscape of T-cell exhaustion heterogeneity within the tumor microenvironment revealed a progressive roadmap of hierarchical dysfunction associated with prognosis and therapeutic efficacySemantic proximity Read ↗

A Multi-Omics Analysis of an Exhausted T Cells’ Molecular Signature in Pan-CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.